EA202091035A1 - COMBINATIONS OF EDARAVON FOR THE TREATMENT OF ISCHEMIC BRAIN DAMAGE - Google Patents

COMBINATIONS OF EDARAVON FOR THE TREATMENT OF ISCHEMIC BRAIN DAMAGE

Info

Publication number
EA202091035A1
EA202091035A1 EA202091035A EA202091035A EA202091035A1 EA 202091035 A1 EA202091035 A1 EA 202091035A1 EA 202091035 A EA202091035 A EA 202091035A EA 202091035 A EA202091035 A EA 202091035A EA 202091035 A1 EA202091035 A1 EA 202091035A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
treatment
nervous system
central nervous
edaravon
Prior art date
Application number
EA202091035A
Other languages
Russian (ru)
Inventor
Кирилл Константинович Сыров
Владимир Викторович НЕСТЕРУК
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA202091035A1 publication Critical patent/EA202091035A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к комбинации эдаравона по меньшей мере с одним веществом, выбранным из группы, включающей эбселен, ресвератрол, мочевую кислоту, дегидроаскорбиновую кислоту и натриевую соль дисуфентона для лечения острого нарушения мозгового кровообращения (ОНМК) - инсульта по ишемическому типу с целью уменьшения неврологической симптоматики, расстройств в выполнении повседневных действий пациента, а также функциональных расстройств ЦНС, связанных с инсультом; бокового амиотрофического склероза (БАС) с целью замедления прогрессирования функциональных расстройств ЦНС; транзиторной ишемической атаки (ТИА) в остром периоде и после перенесенной атаки; хронической ишемии мозга; когнитивных и поведенческих расстройств при сосудистых заболеваниях головного мозга.The present invention relates to a combination of edaravone with at least one substance selected from the group consisting of ebselen, resveratrol, uric acid, dehydroascorbic acid and disufenton sodium salt for the treatment of acute cerebrovascular accident (ACVI) - ischemic stroke in order to reduce neurological symptoms , disorders in the daily activities of the patient, as well as functional disorders of the central nervous system associated with stroke; amyotrophic lateral sclerosis (ALS) in order to slow the progression of functional disorders of the central nervous system; transient ischemic attack (TIA) in the acute period and after the attack; chronic cerebral ischemia; cognitive and behavioral disorders in vascular diseases of the brain.

EA202091035A 2017-11-03 2018-10-31 COMBINATIONS OF EDARAVON FOR THE TREATMENT OF ISCHEMIC BRAIN DAMAGE EA202091035A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017138466A RU2693627C2 (en) 2017-11-03 2017-11-03 Edaravon combination for treating ischemic brain injury
PCT/RU2018/000718 WO2019088881A1 (en) 2017-11-03 2018-10-31 Edaravone combinations for treating ischemic brain damage

Publications (1)

Publication Number Publication Date
EA202091035A1 true EA202091035A1 (en) 2020-07-27

Family

ID=66332178

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091035A EA202091035A1 (en) 2017-11-03 2018-10-31 COMBINATIONS OF EDARAVON FOR THE TREATMENT OF ISCHEMIC BRAIN DAMAGE

Country Status (3)

Country Link
EA (1) EA202091035A1 (en)
RU (1) RU2693627C2 (en)
WO (1) WO2019088881A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220409588A1 (en) * 2019-07-18 2022-12-29 Bdr Pharmaceuticals International Private Limited Oral formulations of edaravone and method of manufacturing thereof
WO2022042644A1 (en) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 Edaravone sustained-release pharmaceutical composition, preparation method, and application
WO2024038471A1 (en) * 2022-08-18 2024-02-22 Bdr Pharmaceuticals International Private Limited Oral formulations of edaravone and improved method of manufacturing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
WO2001089520A2 (en) * 2000-05-19 2001-11-29 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
FR2822238B1 (en) * 2001-03-16 2003-08-29 Gemac METHOD AND KIT FOR MONITORING NEURODEGENERATIVE DISEASES
JP5098051B2 (en) * 2007-04-05 2012-12-12 Ｓｂｉファーマ株式会社 Mitochondrial disorder brain disease therapeutic agent and diagnostic agent
CN101524352A (en) * 2008-03-04 2009-09-09 江苏先声药物研究有限公司 Composition containing 3-methyl-1-phenyl-2-pyrazoline-5-ketone
CN104546883B (en) * 2014-12-31 2019-06-11 广东药科大学 Preparation and application of the flavonols as Brain targeting synergist

Also Published As

Publication number Publication date
RU2017138466A (en) 2019-05-06
RU2017138466A3 (en) 2019-05-06
WO2019088881A1 (en) 2019-05-09
RU2693627C2 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
EA202091035A1 (en) COMBINATIONS OF EDARAVON FOR THE TREATMENT OF ISCHEMIC BRAIN DAMAGE
MY194054A (en) Substituted imidazo-quinolines as nlrp3 modulators
EA201400976A1 (en) BENZODIOXANES IN COMBINATION WITH OTHER ACTIVE MEANS TO INHIBIT LEUKOTRIEN PRODUCTION
EA201690212A1 (en) METHODS OF TREATMENT OR PREVENTION OF OPHTHALMIC PATHOLOGICAL CONDITIONS
EA201391315A1 (en) GUANIDINE CONNECTION
MX2015012435A (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders.
EA201991375A1 (en) BICYCLO [1.1.1] PENTANE KINASE INHIBITORS CONTAINING A DOMAIN WITH TWO LEUCINE "Zipper" (DLK) FOR THE TREATMENT OF THE DISEASE
EA201892008A1 (en) CONNECTIONS AND METHODS OF TREATMENT OF NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS
WO2014160871A8 (en) Methods and agents for treating alzheimer's disease
EA201891152A1 (en) EXTRACELLULAR VESICULES OF NERVOUS CELLS
EA201990450A1 (en) KINASE INHIBITORS CONTAINING A DOMAIN WITH TWO LEUCINE "Zipper" (DLK) FOR THE TREATMENT OF A DISEASE
MA41758A (en) INFERTILITY TREATMENT METHODS
EA202092719A1 (en) BENZENESULPHONAMIDE COMPOUNDS AND THEIR APPLICATION AS THERAPEUTIC AGENTS
EA201600288A1 (en) SUBSTITUTED PHYLALANINE DERIVATIVES
EA201892536A1 (en) PHARMACEUTICAL MEDIA CONTAINING MICRORNA FOR APPLICATION IN THE TREATMENT OF FIBROZAL DISEASES CAUSED BY HYPERGLYCEMIA
EA201892153A1 (en) CONDENSED PENTACYCLIC DERIVATIVES OF IMIDAZOLE AS TNF ACTIVITY MODULATORS
EA202092002A1 (en) 5-HETEROARYL SUBSTITUTED INDAZOL-3-CARBOXAMIDES AND THEIR PREPARATION AND APPLICATION
CU24647B1 (en) MODULATORS OF THE HETEROAROMATIC NMDA RECEPTOR
EA201890590A1 (en) PERMITTING IN THE BRAIN DERIVATIVE OF OXIMA CHROMONA FOR THE TREATMENT OF LEU WATER-INDUCED DYSKINESIA
EA201691788A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS
EA201591021A1 (en) 4-HYDROXY-2-METHIL-5- (PROPAN-2-ILIDEN) CYCLOGEX-3-ENEKARBALDEHYDE IN PREVENTION AND TREATMENT OF COGNITIVE, NEURODEGETERATIVE OR NEURAL DISEASES
EA202092305A1 (en) CONNECTIONS AS TLR2 ALARM MODULATORS
MA49140A (en) MERGED HETEROAROMATIC-ANILINE COMPOUNDS FOR THE TREATMENT OF DERMAL DISORDERS
EA201892144A1 (en) CONDENSED HEXACYCLIC DERIVATIVES OF IMIDAZOL AS A TNF ACTIVITY MODULATOR
EA201890234A1 (en) FUSED MOLECULES